Skip to main content

Table 1 Baseline patient characteristics, stratified by disease duration

From: Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials

Variable All patients (n = 93) Placebo (n = 48) CYC (n = 45) p Value
Age, yr, mean (SD) 47.19 (11.72) 47.43 (13.24) 46.93 (10.00) 0.8388
Female sex, n (%) 68 (73.12) 34 (70.83) 34 (75.56) 0.6077
White race, n (%) 71 (76.34) 38 (79.17) 33 (73.33) 0.6764
Type of SSc, n (%)     
 Limited 37 (39.78) 19 (39.58) 18 (40.00) 0.9673
 Diffuse 56 (60.22) 29 (60.42) 27 (60.00)  
Disease duration, yr, mean (SD) 3.27 (2.24) 3.30 (1.97) 3.24 (2.52) 0.8895
Antibodies (n = 55), n (%)a     
 Scl-70 22 (32.84) 13 (35.14) 9 (30.00) 0.6563
 Anti-centromere/anti-RNA polymerase III 14 (20.90) 5 (13.51) 9 (30.00) 0.0988
FVC, % predicted, mean (SD) 67.73 (11.90) 68.86 (11.91) 66.53 (11.90) 0.3497
DLCO, % predicted, mean (SD) 46.32 (12.75) 46.04 (12.41) 46.61 (13.24) 0.8303
MRSS, mean (SD) 15.22 (11.02) 14.56 (10.52) 15.91 (11.60) 0.5580
Mahler’s BDI focal score (0–12), mean (SD) 5.67 (1.76) 5.48 (1.99) 5.90 (1.45) 0.2613
HAQ-DI (0–3), mean (SD) 0.82 (0.67) 0.70 (0.67) 0.96 (0.64) 0.0629
SF-36 PCS (0–100), mean (SD) 33.70 (11.29) 34.63 (10.98) 32.68 (11.66) 0.4099
SF-36 MCS (0–100), mean (SD) 49.15 (10.94) 49.23 (11.17) 49.06 (10.82) 0.9413
HRCT-determined disease extent, mean (SD)     
 Maximum fibrosis score (0–4) 1.99 (1.05) 1.96 (1.07) 2.02 (1.03) 0.7700
 Maximum honeycombing (0–4) 0.40 (0.58) 0.42 (0.54) 0.37 (0.62) 0.9592
 Maximum ground-glass opacity (0–4) 0.73 (0.76) 0.73 (0.71) 0.72 (0.83) 0.7101
Visual maximum fibrosis score, n (%)     0.2007
 0 % 7 (7.69) 4 (8.33) 3 (6.98)  
 1–25 % 25 (27.47) 15 (31.25) 10 (23.26)  
 26–50 % 25 (27.47) 9 (18.75) 16 (37.21)  
 51–75 % 30 (32.97) 19 (39.58) 11 (25.58)  
 76–100 % 4 (4.40) 1 (2.08) 3 (6.98)  
Goh and Wells unadjusted stratification for lung involvement (consensus of 3 readers), n (%)     0.5298
 <20 % 38 (44.71) 22 (47.83) 16 (41.03)  
 >20 % 47 (55.29) 24 (52.17) 23 (58.97)  
 Goh’s adjusted minimal disease, n (%) 20 (21.98) 8 (17.02) 12 (27.27) 0.3540
 Goh’s adjusted extensive disease, n (%) 71 (78.02) 39 (82.98) 32 (72.73)  
CAD scores     
 QILD WL, mean (SD) 34.71 (15.67) 34.96 (16.95) 34.44 (14.35) 0.8771
 QILD ZM, mean (SD) 58.84 (20.94) 58.53 (21.33) 59.19 (20.75) 0.8833
 QLF WL, mean (SD) 9.80 (9.83) 10.11 (10.60) 9.47 (9.02) 0.7591
 QLF ZM, mean (SD) 26.44 (21.82) 25.23 (21.44) 27.77 (22.40) 0.5851
  1. FVC forced vital capacity, DLCO diffusing capacity for carbon monoxide, MRSS modified Rodnan skin thickness score, BDI Baseline Dyspnea Index, HAQ-DI Health Assessment Questionnaire Disability Index, PCS Physical Component Score, SF-36 36-item Short Form Health Survey, MCS Mental Component Score, HRCT high-resolution computed tomography, CAD computer-aided diagnosis, QILD quantitative assessment of total extent of interstitial lung disease, QLF quantitative percentage of lung fibrosis, ZM zone of maximal involvement, WL whole lung, SD standard deviation, SSc systemic sclerosis, CYC cyclophosphamide
  2. a p < 0.05